Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

241
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
241
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

235
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
235
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

335
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
335
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

280
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
280
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

270
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
270
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

19
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
19

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

Therapeutic innovation & regulatory science·2026
Same author

Niraparib PBPK modeling to predict optimal dosage in patients with hepatic impairment.

Frontiers in pharmacology·2026
Same author

Quantitative systems pharmacology model of B cell immune response in mouse.

Frontiers in immunology·2026
Same author

ABO-Incompatible Platelet Transfusions and Mortality Risk in Patients With Intracranial Hemorrhage.

Neurosurgery·2026
Same author

Multiscale physiologically-based model of age-dependent CD4+ T-lymphocyte homeostasis.

Frontiers in immunology·2026
Same author

Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibody.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

A Bayesian Optimal Interval Design Considering Efficacy and Toxicity in Early Phase Basket Trials.

Pharmaceutical statistics·2026
Same journal

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same journal

Harmonic Fowlkes-Mallows Index for Medical Diagnostics Tests and Optimal Cut-Off Point Selection of Binary Diseases.

Pharmaceutical statistics·2026
Same journal

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same journal

Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints.

Pharmaceutical statistics·2026
Same journal

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
See all related articles

Related Experiment Video

Updated: Feb 15, 2026

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.6K

Integrating dose estimation into a decision-making framework for model-based drug development.

James Dunyak1, Patrick Mitchell1, Bengt Hamrén2

  • 1Astrazeneca, Waltham, MA, USA.

Pharmaceutical Statistics
|January 12, 2018
PubMed
Summary
This summary is machine-generated.

This study introduces a model-based framework to improve go/no-go decisions in drug development by integrating efficacy and dose-response accuracy. This approach aims to reduce clinical development risks and costs through better scientific decision-making.

More Related Videos

Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

2.6K
Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

16.6K

Related Experiment Videos

Last Updated: Feb 15, 2026

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.6K
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

2.6K
Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

16.6K

Area of Science:

  • Pharmacometrics
  • Drug Development
  • Clinical Trial Design

Background:

  • Pharmaceutical go/no-go decisions rely heavily on effect size for commercial targets.
  • Accurate dose and dose-response knowledge is crucial, as incorrect dosing risks clinical and commercial failure.
  • Existing decision frameworks can be enhanced by integrating efficacy and dose-response estimation accuracy.

Purpose of the Study:

  • To develop and illustrate a model-based decision framework for go/no-go decisions in drug development.
  • To integrate both efficacy and dose-response estimation accuracy into the decision-making process.
  • To characterize development risks more comprehensively by considering dose-response uncertainties.

Main Methods:

  • Developed a decision framework using prespecified target and lower reference values for efficacy and dose accuracy.
  • Incorporated a set of dose-response models and employed model averaging to address early-stage knowledge gaps.
  • Illustrated the framework's operating characteristics through simulation studies.
  • Applied the decision approach to a post hoc analysis of Phase 2 data for naloxegol.

Main Results:

  • The model-based approach provides a structured method for evaluating drug development risks.
  • Integration of efficacy and dose-response accuracy enhances the go/no-go decision process.
  • Model averaging effectively handles dose-response uncertainties in early development.

Conclusions:

  • The proposed framework offers a more complete characterization of development risk for go/no-go decisions.
  • This model-informed approach supports scientific decision-making, potentially increasing efficiency and reducing costs in drug development.
  • The naloxegol case study demonstrates the practical application of this enhanced decision framework.